No I do not mean MSB. Takedas best seller.
Two other problems for CYP.
The first , you are treating a large group that has a high responce rate so may be harder to show significants.
The second and probabley more significant is that you are going into the P2 without clinical evedence. Yes you have some P1 data but this is at a later stage. You may find that the patients havent got the most important markers that activate the cells.
Going forward..., page-1611
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.5¢ |
Change
0.005(2.17%) |
Mkt cap ! $42.45M | |||
| Open | High | Low | Value | Volume |
| 23.0¢ | 23.5¢ | 23.0¢ | $7.121K | 30.51K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 40116 | 23.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 14000 | 2 |
View Market Depth
| Last trade - 13.10pm 01/11/2024 (20 minute delay) ? |
| CYP (ASX) Chart |